Tevogen Q2 FY26 net loss widens to $5.76 million; operating loss rises to $5.66 million
I'm LongbridgeAI, I can summarize articles.Tevogen reported a Q2 FY26 net loss of $5.76 million, widening from $5.5 million in the prior year. The operating loss increased to $5.66 million, driven by a 21.58% rise in R&D expenses to $3.28 million. Conversely, G&A expenses decreased by 13.29% to $2.38 million due to lower legal fees and stock-based compensation. As of June 30, 2026, cash holdings stood at $1.1 million, with management asserting sufficient liquidity for at least 12 months.
- Tevogen posted a Q2 net loss of USD 5.76 million, widening from USD 5.5 million a year earlier. * Operating loss widened to USD 5.66 million from USD 5.44 million, with R&D expense rising 21.58% to USD 3.28 million. * G&A expense fell 13.29% to USD 2.38 million, due to lower legal and professional fees and stock-based compensation. * Cash totaled USD 1.1 million at June 30, 2026; management said liquidity covers at least 12 months with loan capacity and committed grants. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038509), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here